Conclusions Based on our initial data, we conclude that the Trevo NXT is an effective and safe tool for mechanical thrombectomy especially when used for combined approaches.

Disclosure Nothing to disclose

**EP53**

THE NOVEL TENZING INSERTS – THE SEAMLESS WAY TO REACH THE CLOT IN LARGE AND MIDDLE VESSEL CEREBRAL OCCLUSIONS – PRELIMINARY EXPERIENCE


Introduction-Objectives To report the feasibility, safety and efficacy in utilizing the novel Tenzing inserts during stroke thrombectomy in order to reach the clot with large bore catheters, without need for crossing.

Aims-Methods The distal trackability of the new generation of super large bore aspiration catheters is provided by the newly engineered Tenzing inserts, which present virtually atraumatic self-centering soft tapered tip, capable to navigate the tortuous cervico-cranial vasculature with very infrequently necessity of an inner microwire, the extremely large shaft which almost zeroes the step-off with the aspiration catheters, reducing the risk to get stuck at the level of vascular ledges/bifurcations and the unnecessary to cross the embolus, which significantly reduce the risk of downstream clot embolization. The Tenzing 7 is compatible with large bore aspiration catheters, while the Tenzing 8 matches the 088’ HiPoint super large bore catheter, which in combination with the Base Camp guiding catheter is utilized for the Mount Everest Technique (MET).

Results We have utilized this novel insert in 20 patients with large and moderate vessel occlusions involving the anterior (19; 8 ICA, 8 MCA-M1, 3 MCA-M2) and posterior1 circulation with 100% efficacy. No embolization in unaffected vascular territories or symptomatic SAH has been observed.

Conclusions In our preliminary experience, the utilization of the novel Tenzing inserts proved to be extremely effective in reaching the clot with large and super large bore catheters, without the necessity to cross the embolus as well as without encountering the issue of getting stuck at the level of vascular ledges/bifurcations.

Reference


Disclosure Nothing to disclose

**EP54**

UTILITY OF DRUG-ELUTING COROFLEX ISAR STENT IN INTRACRANIAL ATHEROSCLEROTIC DISEASE: A SINGLE CENTER EXPERIENCE IN 147 PATIENTS

A El Mekabaty, V Hellstern, M Auguilier-Perez, H Henkes. Diagnostic and Interventional Neuroradiology, Klinikum Stuttgart Katharinenhospital, Stuttgart, Germany

Introduction Intracranial atherosclerotic disease (ICAD) is a major cause of stroke worldwide. Different treatment regimens, including medical treatment (e.g. dual antiplatelet inhibition) and endovascular treatment are available. We aim to investigate the safety and efficacy of the drug-eluting, balloon-mounted Coroflex ISAR stent in patients with ICAD.

Methods A retrospective analysis of patients with ICAD and attempted implantation of Coroflex ISAR stent in our institution from 2014 to 2020 was performed.

Results A total of 147 patients were included (74.1% males, average age 70 years ‘range 47–93’). Median baseline modified Rankin score (mRS) was 0 (interquartile range ‘IQR’ 0–1) and median pretreatment mRS was 2 (IQR 1–4). Lesions treated were located in the ICA (42.9%), V4 segment (36.1%), basilar artery (12.2%) and M1 segment (8.8%). Stent was successfully implanted in 92.6% (137/147) and the vessel stenosis was reduced from a mean of 76% ‘range 50–99’ to 36% ‘range 0–82’. Short-term follow-up was available in 77.7% of patients after a median of 3 months ‘IQR 1–5’ and long-term follow-up was available in 63.3% (93/147) after a median of 24 months ‘IQR 14–40’. In-Stent stenosis occurred in 13.9% (16/115), recurrent stroke in 9.5% (11/115) and asymptomatic intracranial hemorrhage in 3.4% (5/147). Over-all mortality was 4.1% (6/147).

Conclusion The drug-eluting, balloon-mounted Coroflex ISAR is a safe and effective treatment option for ICAD. The overall recurrent stroke rate was 9.5% and mortality was 4.1%. Further work is needed to better identify ICAD patients for stenting.

References


Disclosure Nothing to disclose

**EP55**

KEEP IT SIMPLE: THE SNACE (SOFIA NON-WIRE ASPIRATION CONTRAST ENHANCEMENT) TECHNIQUE FOR THE ENDOVASCULAR MANAGEMENT OF ACUTE ISCHEMIC STROKE

B Pabon, V Torres, J Mejia, M Patiño, O Vargas, N Serna, J Pelaez. Angioteam, Medellin, Colombia


Methods 38 prospective patients with ELVO at four institutions were included in the study. The SNACE technique was utilized in all patients. Procedural and clinical data were analyzed.

Results The SNACE approach using SOFIA 6 Plus Catheter was successful in achieving Thrombolysis in Cerebral Infarction (TICI) 2b or 3 revascularizations in 88% of cases. The first Pass effect was obtained in 75%. The average time from groin puncture to at least TICI 2b re cannalization was 17 min. National Institutes of Health Stroke Scale (NIHSS) score average at the onset of 16 and improved to a median NIHSS...
score at discharge of 5.5. We did not find intra-procedural complications and two symptomatic intracerebral hemorrhages were recorded postoperatively.

Discussion The SNACE technique is a simple, fast, safe, and effective method that has reduced the requirements to multiple passes and avoiding the use of expensive materials to reach the occlusion site. SNACE is a replicable approach without additional training requirements.

REFERENCES

Disclosure Boris Pabon proctorship con MEDTRONIC, Microvention Consultant MIVI

EP56 TARGETED SINGLE LOW-DOSE INTRA-ARTERIAL BEVACIZUMAB FOR STEROID-REFRACTORY RADIATION NECROSIS OF THE BRAIN

1SR Dashti, 2RJ Kadner, 3BS Folley, 4Al Sheehan, 5RA Kryscio, 6NB Carter, 7LE Shields, 8BM Plato, 9RV La Rocca, 10AC Spalding, 11TL Yao, 12AF Fraser. Cerebrovascular and Endovascular Neurosurgery Institute, Norton Neuroscience Institute, Norton Healthcare; 1DIP Imaging; 2Norton Neuroscience Institute, Norton Healthcare, Louisville, KY; 3Department of Neurological Surgery, University of Virginia, Charlottesville, VA; 4Department of Neurology, University of Kentucky College of Medicine; 5Department of Statistics, University of Kentucky, Lexington; 6Department of Radiation Oncology, University of Kentucky; 7Department of Neurosurgery, University of Kansas Medical Center, Kansas City, KS; 8Department of Radiology, University of New Mexico, Albuquerque; 9Department of Neurology, Radiology, and Neuroscience, University of Kentucky, Lexington, KY, USA

Introduction Phase II, single-arm, prospective trial in patients with steroid-refractory brain radiation necrosis (RN).

Aim Evaluate safety and efficacy of single low-dose targeted intra-arterial (IA) bevacizumab following osmotic blood-brain barrier disruption (BBBD).

Methods Following BBBD, 10 adults underwent targeted 2.5 mg/kg IA bevacizumab. RN, edema, headache, steroid dependency were quantified at baseline and 12-months. Data (mean ±SEM) analyzed using Wilcoxon signed-rank tests and one-way repeated measures ANOVA test of linear trend. Null hypothesis rejected for p<0.05.

Results RN decreased by 74.4±5.2% with significant linear trend [F(1)=10.940, n=8, p=0.013, effect size=0.610]. Vascular edema decreased by 50.1±13.2% but linear trend did not reach significance [p=0.102]. Headache decreased by 84.4±6.5% with significant linear trend [F(1)=9.299, n=8, p=0.019, effect size=0.571]. Only 1/10 patients were steroid dependent 12-months after bevacizumab. 0/10 died or exhibited AEs attributed to bevacizumab alone. 4 AEs of short duration and moderate severity were probably related to BBBD (tonic/clonic seizures with altered mental status 2-hours post-procedure) or BBBD+bevacizumab (mono-ocular blurred vision with diplopia on day 1). 2/10 patients who experienced marked improvement at 3 months exhibited RN recurrence requiring intervention (surgery at 10-months; 4-cycles IV bevacizumab at 11-months, respectively).

Conclusions Single low-dose targeted intra-arterial bevacizumab led to durable radiographic and clinical improvement of RN during 12-months follow-up in 8/10 patients. To our knowledge this is the first prospective report of this novel approach in adults. Randomized trials are needed comparing targeted low-dose IA bevacizumab to multi-cycle IV bevacizumab at higher doses to determine which is longer-lasting, safer, cheaper alternative in brain RN.

REFERENCES

Disclosure Nothing to disclose

EP57 REAL WORLD EXPERIENCE OF THE MIVI Q™ ASPIRATION CATHETER

J Wareham. Department of Interventional Neuroradiology, North Bristol NHS Trust, Bristol, UK

10.1136/neurintsurg-2021-ESMINT.56

Introduction The MIVI Q™ Aspiration Catheter offers a range of novel aspiration catheters that have been shown to achieve significantly greater flow rates than other intracranial aspiration catheters in vitro.1 Little published data however exists as to how this translates in real world practice.

Aim We describe our initial experience with the MIVI Q in emergent large (TICA,M1,BA) and medium (A1,2,2,M2,3,P1,2) vessel occlusive stroke.

Methods Data was collated from a prospectively maintained database. Patient demographics, thrombectomy technique, reperfusion scoring and disposition were assessed.

Results Twenty-nine target vessel occlusions occurring in 27 patients were included. Of these 29, 16 (55%) were large vessel and 13 (45%) medium vessel occlusions. TICI 2/3 was achieved in 15 (94%) of large vessel occlusions with 10 (62.5%) occurring on first pass, 5 (50%) of which incorporated the simultaneous use of a stent retriever. Successful reperfusion (TICI 2/3) was achieved in 10 (77%) medium vessel occlusions with all 10 (77%) occurring on first pass. A stent retriever was used in combination in 1 (10%). In one patient, an M2 occlusion was withdrawn proximally into the M1. This was removed with aspiration and a stent retriever. No cases of symptomatic intracranial hemorrhage were experienced.

Conclusion The MIVI Q is both safe and effective. Our real world experience supports the superior flow rates demonstrated in vitro and translates into high rates of recanalisation in large and medium vessel occlusive stroke in clinical practice.

REFERENCE

Disclosure Consultant for MIVI Neuroscience